207_Combined course Presentations

Neoadjuvant therapy

Newly diagnosed tumor

Residual tumor

THERAPY

Curative intent

• Contras:

• Pro:

– Low rate of pCR (ER+) – Select subgroups – Implication for surgeons and radiation oncologists

– Increasing rate of BCT – Pathological complete response – Drug develomment

Preferred option in some subtypes (triple negative ed HER2 positive)

15